#1 Clinical Trials Search in Europe

Ribonucleic Acid K30

This article discusses a clinical trial investigating the effectiveness of two treatments, 2LEBV® and 2LXFS®, in reducing fatigue and other symptoms associated with Epstein-Barr Virus (EBV) infection. The study aims to compare these treatments against a placebo in a randomized, double-blind setting, focusing on patients aged 12 and older who experience significant fatigue and other EBV-related symptoms.

Table of Contents

What is RIBONUCLEIC ACID K30?

RIBONUCLEIC ACID K30 is one of the active substances in a medication called 2LXFS[1]. This medication is being studied as a potential treatment for people infected with the Epstein-Barr Virus (EBV) who are experiencing significant fatigue. Ribonucleic acid, also known as RNA, is a type of molecule that plays a crucial role in various biological processes in our bodies[1].

Epstein-Barr Virus and Fatigue

The Epstein-Barr Virus is a common virus that can cause various symptoms, including severe fatigue. When you’re infected with EBV, your body’s immune system fights the virus, which can lead to feelings of exhaustion that last for a long time[1]. This fatigue can significantly impact your daily life and overall well-being.

Clinical Trial Overview

A clinical trial is currently being conducted to evaluate how effective 2LXFS (which contains RIBONUCLEIC ACID K30) is in reducing fatigue in patients with EBV infection[1]. This study is:

  • Randomized: Participants are randomly assigned to different groups
  • Placebo-controlled: Some participants receive the actual medication, while others receive a placebo (a substance with no active ingredients)
  • Double-blind: Neither the participants nor the researchers know who is receiving the actual medication or the placebo

Potential Benefits

The main goal of this study is to see if 2LXFS can help reduce the severity of fatigue in people with EBV infection[1]. Researchers are also looking at other potential benefits, including:

  • Improvements in other symptoms related to EBV infection
  • Changes in the immune system, particularly in the types and numbers of certain immune cells (lymphocytes)
  • Changes in the levels of antibodies (IgG) that your body produces in response to the EBV infection

Who Can Participate?

The study is looking for participants who meet certain criteria[1]:

  • Males or females aged 12 years and older
  • Experiencing significant fatigue for 1 month or more
  • Have at least two other symptoms related to EBV infection (such as fever, sore throat, swollen lymph nodes, etc.)
  • Have a positive blood test for EBV

However, some people may not be able to participate if they:

  • Have previously used 2LXFS or similar treatments
  • Are taking certain medications that affect the immune system
  • Are pregnant or breastfeeding
  • Have certain medical conditions or are undergoing specific treatments

What to Expect During the Trial

If you participate in this trial, you can expect the following[1]:

  • Regular check-ups and evaluations over a period of 12 months
  • Completion of questionnaires about your fatigue and other symptoms
  • Blood tests to check your immune system and antibody levels
  • You’ll be given either 2LXFS or a placebo to take as directed

Safety Considerations

As with any medical treatment, there may be potential risks or side effects. The researchers will be closely monitoring all participants for any adverse events throughout the study[1]. It’s important to report any unusual symptoms or changes in your health to the study team promptly.

Remember, participating in a clinical trial is voluntary, and you can withdraw at any time. Always discuss with your healthcare provider before deciding to participate in any clinical trial.

Aspect Details
Study Type Randomized, placebo-controlled, double-blind clinical trial
Treatments 2LEBV® and 2LXFS®/2LEBV® compared to placebo
Main Condition Epstein-Barr Virus (EBV) infection with fatigue
Primary Outcome Fatigue severity at 6 months (end of treatment)
Secondary Outcomes Other fatigue dimensions, EBV-related symptoms, lymphocyte typing, antibody levels
Participant Age 12 years and older
Key Inclusion Criteria Significant fatigue for 1+ month, 2+ other EBV symptoms, positive EBV serology
Key Exclusion Criteria Recent homeopathic treatments, immunosuppressive therapy, severe immunodeficiency
Follow-up Duration 12 months

FAQ

  • What is the main goal of this clinical trial? The main goal is to compare the effectiveness of 2LEBV® or 2LXFS®/2LEBV® treatments versus a placebo in reducing fatigue severity in patients with EBV infection at the end of the treatment period.
  • Who can participate in this study? Participants must be 12 years or older, experiencing significant fatigue for at least a month, have at least two other EBV-related symptoms, and test positive for EBV antibodies. They should not have received certain treatments recently and must not have severe immunodeficiency diseases.
  • How long does the study last? The study includes follow-up visits at 3 months, 6 months (end of treatment), and 12 months after starting the treatment.
  • What symptoms besides fatigue are being evaluated? The study evaluates various EBV-related symptoms such as exhaustion, fever, loss of appetite, nausea, sore throat, muscle weakness, headaches, sleep disorders, and others. It also looks at changes in lymphocyte levels and antibodies.
  • How is the effectiveness of the treatments measured? The primary measure is the general fatigue scale of the MFI-20 questionnaire at the end of treatment. Secondary measures include other fatigue-related scales, EBV-related symptoms, changes in lymphocyte typing, and antibody levels.

Ongoing Clinical Trials on Ribonucleic Acid K30

  • Study on the Effectiveness of 2LEBV and 2LXFS for Reducing Fatigue in Patients with Epstein-Barr Virus Infection

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Epstein-Barr Virus (EBV): A common virus that can cause infectious mononucleosis and is associated with certain cancers. It often leads to fatigue and other symptoms.
  • Asthenia: A medical term for weakness or lack of energy, which is a common symptom in EBV infections.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs.
  • Double-blind study: A type of clinical trial where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving the placebo.
  • Serology: A blood test to detect the presence of antibodies related to specific infections.
  • Lymphocyte typing: A test to identify and count different types of white blood cells, which can indicate how the immune system is functioning.
  • IgG and IgM: Types of antibodies produced by the immune system in response to infections. IgM appears early in infections, while IgG indicates past or chronic infection.
  • MFI-20 questionnaire: A tool used to measure different aspects of fatigue in patients.
  • Immunosuppressive treatment: Medications that lower the body's immune response, often used in treating autoimmune diseases or preventing organ rejection after transplants.
  • Micro-immunotherapy: A type of therapy that aims to regulate the immune system using low doses of immune messengers like cytokines, growth factors, or nucleic acids.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-2lebv-and-2lxfs-for-reducing-fatigue-in-patients-with-epstein-barr-virus-infection/